Key Takeaways Resmed is benefiting from strong global demand for AirSense 10 and 11, driving higher device sales growth.RMD reported 10% sales growth across regions in Q1 FY26, supported by expansion in key international markets. Resmed ended Q1 FY26 with $1.38B in cash, low debt levels and a total debt-to-capital ratio of 6.3%. Resmed Inc. (RMD) continues to see strong demand for its market-leading AirSense 10 and AirSense 11 sleep devices. Expansion into international markets appears highly promising, sup ...

Group 1: Company Highlights - Above Food Ingredients Inc. Warrants (OTC:ABVEW) leads the market with an 81.74% increase, reaching $0.69, focusing on disruptive agriculture and international operations in sustainable food [1][7] - SMX (NASDAQ:SMX) follows with a 74.64% rise to $33.67, known for its brand protection and authentication technology, benefiting from innovative anti-counterfeit solutions and a strong financial outlook for 2026 [2][7] - Bristol-Myers Squibb Company Ce (CELG-RI) saw a 71.53% increase to $0.11, driven by advancements in small molecules and biologics, emphasizing drug manufacturing and healthcare treatments [3] - EUDA Health Holdings Limited (EUDAW) experienced a 67.29% rise to $0.12, focusing on virtual consults for non-emergency medical issues, gaining traction in the digital health sector [4] - Momentus Inc. (NASDAQ:MNTS) saw a 61.75% increase to $15.9, specializing in space transportation and in-orbit servicing, supported by industry developments and a recent $5 million private placement [5][7] Group 2: Industry Trends - The market is witnessing dynamic movements with sectors like sustainable food and space exploration capturing investor interest, highlighting the importance of unique industry positions and strategic developments [6]

SAN JOSE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substantial investm ...

LAKEWOOD, NJ, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) (the “Company”) today announced the unanimous Board approval for its formation of EZRA International Group, a new division focused on acquiring controlling stakes and accelerating growth of high-tech Israeli companies, with an initial focus on the Cybersecurity, AI & Data Analytics, FinTech & InsurTech, as well as MedTech & Digital Health sectors. Through this initiative, the Company intends to pursue a structured pat ...

Economic Data Release - The week will begin with ISM Manufacturing PMI and ISM Manufacturing Prices data for December on Monday [2] - S&P Global Services PMI and ISM Non-Manufacturing PMI for December will be released on Tuesday [2] - JOLTS Job Openings for November and ADP Nonfarm Employment numbers for December are scheduled for Wednesday [2] - Initial Jobless Claims data will be released on Thursday [2] - Nonfarm Payrolls and unemployment numbers for December are due on Friday [2] Earnings Reports - Constellation Brands, Marks & Spencer, Albertsons, and Applied Digital will report their earnings on Wednesday [3][4] - Tesco PLC is set to report earnings on Thursday [4] Market Events - The CES conference in Las Vegas will focus on AI, robotics, digital health, and mobility, featuring keynote speeches from Nvidia CEO Jensen Huang [5] - IREN Limited and GameStop are expected to experience volatility based on options volume [4] - The analyst quiet period will expire for Lumexa, Wealthfront, JM Group, and Cardinal Infrastructure, allowing analysts to post ratings [4]

Core Insights - Profusa, Inc. has established a new distributor partnership with MedSell in France to commercialize Lumee™ Oxygen tissue monitoring, expanding its reach in the European market [1][2] - The partnership aims to address the needs of approximately 200,000 annual Critical Limb Threatening Ischemia (CLTI) cases in the European Union, with MedSell focusing on hospital and outpatient care settings [1][2] - The collaboration with MedSell complements an existing partnership with a leading vascular surgeon in France, who accounts for about 8% of all CLTI cases in the country [2] Company Strategy - Profusa aims to achieve $200 to $250 million in revenue by 2030, with projected revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027 [3] - The company is focused on executing its commercial strategies, including the introduction of Lumee Oxygen monitoring in Europe starting in Q2 2026, with plans to enter the US market in 2027 [3] - Profusa emphasizes the importance of making its oxygen tissue monitoring platform accessible in both clinical and home settings to enhance patient outcomes and reduce healthcare costs [3] Product Overview - Lumee Oxygen tissue monitoring is designed to measure tissue oxygen perfusion before and during surgical procedures, as well as during follow-up care, addressing a critical unmet clinical need [2] - The device is expected to provide significant value to clinicians by supporting decision-making and patient monitoring throughout the treatment pathway [2] - Profusa's technology is part of a broader initiative to develop tissue-integrated sensors that continuously transmit actionable medical data [4]

Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information.Adds subscription-based business model to product offering with the connected mobile application. Digital offering ad ...

Core Insights - Virtual care is becoming a mainstream healthcare channel, with Hims & Hers Health, Inc. (HIMS) and Teladoc Health, Inc. (TDOC) utilizing digital-first models to enhance access [2][3] Company Overview - HIMS operates as a consumer-first, subscription-based telehealth platform, allowing users to discover treatments online, consult licensed providers, and receive recurring prescriptions through its integrated digital pharmacy [2] - TDOC is a global leader in virtual care, providing services through its Integrated Care segment, which includes virtual medical visits and chronic care programs, as well as BetterHelp, its online therapy platform [2] Stock Performance & Valuation - Over the past three months, HIMS has decreased by 37.4%, while TDOC has declined by 9.7%. However, in the past year, HIMS has increased by 22.1%, contrasting with TDOC's loss of 22.5% [4] - HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 2.9X, above its three-year median of 2.6X, while TDOC's forward sales multiple is at 0.5X, below its median of 0.7X [6] Growth Strategies - HIMS is expanding into low testosterone care, integrating at-home lab testing with personalized treatment plans, and collaborating with Marius Pharmaceuticals to launch an exclusive branded oral testosterone by 2026 [8][10] - The introduction of Hims & Hers Labs aims to enhance customer engagement through diagnostics and biomarker tracking, supporting a more personalized healthcare model [9] - HIMS is also accelerating international expansion, having entered Canada and launched a Weight Loss Programme in the U.K. [10] Teladoc Health's Positioning - TDOC is focusing on building an integrated enterprise-scale virtual care platform, enhancing its offerings in primary care, chronic condition management, and mental health [11] - The company is expanding its hospital capabilities, introducing new tools for operational support and care-team workflows, with a new workplace safety capability expected to launch in early 2026 [12] - TDOC is working on stabilizing performance and improving execution across its segments, with recent results reflecting steady progress [13] Earnings Projections - The Zacks Consensus Estimate for HIMS' 2025 earnings per share (EPS) suggests a 77.8% improvement from 2024 [15] - For TDOC, the 2025 loss per share is expected to improve by 79.7% from 2024 [17] Price Targets - Analysts project an average price target of $45.92 for HIMS, indicating a potential increase of 31.9% from the last close [19] - For TDOC, the average price target is $9.18, suggesting a 27.3% increase from the last close [20] Investment Recommendation - HIMS is viewed as a more stable and financially sound investment opportunity due to its expanding specialty offerings and international growth strategy [22] - TDOC remains a leading enterprise-focused provider but is more exposed to demand cycles and segment-level volatility [23]

Core Insights - AT&T Inc. partners with Sovato to enhance healthcare access by integrating digital health tools with robust connectivity, aiming to improve care delivery in remote areas [1][9] Group 1: Partnership and Technology - The collaboration allows AT&T to transition from a connectivity provider to a significant technology partner in the healthcare sector [1] - Sovato plans to utilize AT&T's extensive network infrastructure to facilitate remote healthcare services, addressing the shortage of healthcare professionals in rural areas [2] - AT&T Business offers secure connectivity solutions, including 5G and cloud services, which are essential for telehealth and remote patient monitoring [3] Group 2: Impact on Healthcare Delivery - The partnership aims to enhance healthcare efficiency and cost management by improving patient data management and reducing long-term healthcare expenses for employers and insurers [5] - AT&T's reliable performance in remote procedures minimizes downtime and ensures patient safety, enabling Sovato to expand its healthcare solutions rapidly [4] Group 3: Competitive Landscape - AT&T faces competition from Verizon and T-Mobile, both of which are also enhancing their digital health offerings through advanced connectivity solutions [6][7] - Verizon is focusing on using 5G and cloud services to support telehealth and remote patient monitoring, while T-Mobile collaborates with digital health providers to improve access for underserved patients [6][7] Group 4: Financial Performance and Estimates - AT&T's stock has increased by 6.5% over the past year, contrasting with a 5.1% decline in the industry [8] - The company trades at a forward price-to-sales ratio of 1.37, which is lower than the industry average of 1.78 [10] - Earnings estimates for 2025 and 2026 have both risen by 0.5%, now projected at $2.06 and $2.25 respectively [11]

BEIJING, Dec. 22, 2025 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners' sales growth and commercial value, today announced that its subsidiary, Beijing Xinmiao Shidai Technology Development Co., Ltd. ("Xinmiao Shidai"), participated in Bank of Guangzhou Co., Ltd.'s ("Guangzhou Bank") 2025 server procurement tender and has been shortlis ...